Related Funds
Fund Name | Location |
Argonaut Holdings | Detroit, Michigan, United States |
Arthurian Life Sciences | England, London, United Kingdom |
Axel Johnson | New York, New York, United States |
Axiometrics | Dallas, Texas, United States |
Binhai Capital | China, Guangdong, Tianjin |
Gateway Partners | Central, Central Region, Singapore |
Growth Catalyst Partners | Chicago, Illinois, United States |
Hengtai Securities | China, Hohhot, Nei Mongol |
Longmont Capital, Ltd | Houston, Texas, United States |
Natural Sciences and Engineering Research Council of Canada (NSERC) | - |
NPIF - FW Capital Debt Finance | Birmingham, England, United Kingdom |
Omni Prime | China, Shanghai |
Osbon Capital Management | Boston, Massachusetts, United States |
Polymath Ventures | Buenaventura, Colombia, Valle del Cauca |
Pulte Home Corp | Atlanta, Georgia, United States |
Ranwa Technologies Co. | - |
RTL Ventures | Hilversum, Noord-Holland, The Netherlands |
Ruiqi Investment | China, Hong Kong, Hong Kong Island |
VinaCapital Ventures | Chicago, Illinois, United States |
Xterra Inc | California, San Francisco, United States |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Weimai Medical | $15M | 25 Sep 2024 | Wuxi Shi, Jiangsu, China | ||
Thorough Images | $15M | 06 Jun 2024 | - | ||
Aoli Biotechnology | 29 Jan 2024 | Shenzhen, Guangdong, China | |||
Salus BioMed | 01 Dec 2023 | Shenzhen, Guangdong, China | |||
Yinghe Brain Science | $100M | 23 Jan 2023 | Shenzhen, Guangdong, China | ||
Dameng Bio | 17 Dec 2021 | Shenzhen, Guangdong, China | |||
Seppo Biotechnology | 01 Jan 2021 | Shenzhen, Guangdong, China | |||
celula | $463K | 09 Oct 2018 | Qingyang District, Sichuan, China | ||
Channel Biotechnology | 01 Jan 2018 | Shenzhen, Guangdong, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Weimai Medical | $15M | 25 Sep 2024 | Wuxi Shi, Jiangsu, China | ||
Thorough Images | $15M | 06 Jun 2024 | - | ||
Aoli Biotechnology | 29 Jan 2024 | Shenzhen, Guangdong, China | |||
Salus BioMed | 01 Dec 2023 | Shenzhen, Guangdong, China | |||
Yinghe Brain Science | $100M | 23 Jan 2023 | Shenzhen, Guangdong, China | ||
Dameng Bio | 17 Dec 2021 | Shenzhen, Guangdong, China | |||
Seppo Biotechnology | 01 Jan 2021 | Shenzhen, Guangdong, China | |||
celula | $463K | 09 Oct 2018 | Qingyang District, Sichuan, China | ||
Channel Biotechnology | 01 Jan 2018 | Shenzhen, Guangdong, China |